- Home
- Results news
- Integrated Proteins
- Q2 FY27 results
Integrated Proteins Q2 FY27 results: net profit up 20.0% to ₹0.06 crore, revenue down 4.8%
Integrated Proteins Ltd reported standalone revenue of ₹4 crore in Q2 FY27, down 4.8% from Q2 FY26 and 62.1% from Q1 FY27. Net profit was ₹0.06 crore and basic EPS was ₹0.03, while the first-half revenue rose 246.2% year on year to ₹14.54 crore.
Key points
- Q2 FY27 standalone revenue was ₹4 crore, down 4.8% from ₹4.20 crore in Q2 FY26 and 62.1% from ₹10.55 crore in Q1 FY27.
- EBITDA was ₹0.07 crore, with an EBITDA margin of 1.8%, against ₹0.09 crore and 2.1% a year earlier.
- Net profit was ₹0.06 crore, up 20.0% from ₹0.05 crore in Q2 FY26, while basic EPS fell 81.2% to ₹0.03.
- H1 FY27 revenue was ₹14.54 crore, up 246.2% from ₹4.20 crore in H1 FY26, and net profit was ₹0.42 crore versus ₹0.05 crore.
- Total assets were ₹25.04 crore on 30 September 2026, while borrowings were ₹3.88 crore and cash was ₹0.11 crore.
How did Integrated Proteins perform in Q2 FY27?
Integrated Proteins reported standalone revenue of ₹4 crore for Q2 FY27, down 4.8% from ₹4.20 crore in Q2 FY26 and 62.1% from ₹10.55 crore in Q1 FY27. EBITDA was ₹0.07 crore and the EBITDA margin was 1.8%, compared with ₹0.09 crore and 2.1% in the year-ago quarter and ₹0.47 crore and 4.4% in the previous quarter.
The company reported profit before tax of ₹0.08 crore and a net profit of ₹0.06 crore in Q2 FY27. Net profit was up 20.0% from ₹0.05 crore in Q2 FY26 but down 83.3% from ₹0.36 crore in Q1 FY27. Basic EPS was ₹0.03, down 81.2% from ₹0.16 year on year and 84.2% from ₹0.19 in the previous quarter. These are standalone figures, and the filing also states that the results are unaudited.
The board approved the unaudited standalone results for the quarter and half year ended 30 September 2026 on 5 November 2026. The statutory auditors carried out a limited review of the results, and the company reported that corresponding previous-period figures had been regrouped or reclassified where necessary to make them comparable.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4 | 10.55 | 4.20 | −4.8% | −62.1% |
| Other income | 0.01 | 0.02 | 0 | −50.0% | |
| Total expenses | 3.92 | 10.08 | 4.13 | −5.1% | −61.1% |
| EBITDA | 0.07 | 0.47 | 0.09 | −22.2% | −85.1% |
| EBITDA margin | 1.8% | 4.4% | 2.1% | −0.3 pp | −2.6 pp |
| Profit before tax | 0.08 | 0.48 | 0.07 | +14.3% | −83.3% |
| Tax | 0.02 | 0.12 | 0.02 | +0.0% | −83.3% |
| Net profit | 0.06 | 0.36 | 0.05 | +20.0% | −83.3% |
| EPS (₹) | 0.03 | 0.19 | 0.16 | −81.2% | −84.2% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Integrated Proteins' costs and profit?
Total expenses were ₹3.92 crore in Q2 FY27, down ₹0.21 crore or 5.1% from ₹4.13 crore in Q2 FY26. Other expenses declined by ₹0.02 crore or 40.0% to ₹0.03 crore, while finance costs fell by ₹0.02 crore to ₹0 crore. Employee cost was unchanged at ₹0.01 crore, and there was no exceptional item in either quarter.
Other income was ₹0.01 crore, up ₹0.01 crore from Q2 FY26, while tax remained unchanged at ₹0.02 crore. Profit before tax increased by ₹0.01 crore or 14.3% to ₹0.08 crore, and net profit increased by ₹0.01 crore or 20.0% to ₹0.06 crore. The EBITDA margin declined by 0.3 percentage points to 1.8%, while the PAT margin increased by 0.3 percentage points to 1.5%.
Against Q1 FY27, total expenses fell by ₹6.16 crore or 61.1%, and other expenses declined by ₹0.03 crore or 50.0%. Other income fell by ₹0.01 crore or 50.0%, and tax fell by ₹0.10 crore or 83.3%. The filing does not state any additional reason for the changes in profit.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 0 | 0 | 0 | |
| Employee cost | 0.01 | 0.01 | 0 | +0.0% |
| Finance costs | 0 | 0.02 | −0.02 | |
| Depreciation | 0 | 0 | 0 | |
| Other expenses | 0.03 | 0.05 | −0.02 | −40.0% |
| Total expenses | 3.92 | 4.13 | −0.21 | −5.1% |
| Other income | 0.01 | 0 | +0.01 | |
| Tax | 0.02 | 0.02 | 0 | +0.0% |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For H1 FY27, Integrated Proteins reported revenue of ₹14.54 crore, up 246.2% from ₹4.20 crore in H1 FY26. Total income was ₹14.56 crore, up 242.6% from ₹4.25 crore, while profit before tax rose by ₹0.49 crore or 700.0% to ₹0.56 crore.
Net profit for the first half was ₹0.42 crore, up ₹0.37 crore or 740.0% from ₹0.05 crore in H1 FY26. Basic EPS increased by ₹0.07 or 43.8% to ₹0.23. The half-year results were unaudited and had received a limited review from the statutory auditors.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 14.54 | 4.20 | +246.2% |
| Profit before tax | 0.56 | 0.07 | +700.0% |
| Net profit | 0.42 | 0.05 | +740.0% |
| EPS (₹) | 0.23 | 0.16 | +43.8% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
Total assets increased to ₹25.04 crore as on 30 September 2026 from ₹20.61 crore on 31 March 2026. Total equity was ₹20.95 crore against ₹20.53 crore, while borrowings rose from nil to ₹3.88 crore. Cash and cash equivalents were ₹0.11 crore, compared with a negative ₹0.02 crore at the previous balance-sheet date, and trade receivables fell from ₹2.06 crore to ₹0.57 crore.
H1 FY27 operating cash flow was negative ₹3.77 crore, against positive ₹3.48 crore in H1 FY26. Investing cash flow was ₹0.01 crore versus ₹0.14 crore, while financing cash flow was ₹3.88 crore compared with negative ₹3.61 crore. Capital expenditure was ₹0 crore in both periods.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 25.04 | 20.61 |
| Total equity | 20.95 | 20.53 |
| Borrowings | 3.88 | 0 |
| Cash and equivalents | 0.11 | −0.02 |
| Inventories | 0 | 0 |
| Trade receivables | 0.57 | 2.06 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −3.77 | 3.48 |
| Cash from investing | 0.01 | 0.14 |
| Cash from financing | 3.88 | −3.61 |
| Capital expenditure | 0 | 0 |
Source: Company's results filing (XBRL).
How has Integrated Proteins done over the last 8 quarters?
Revenue moved unevenly across the reported quarters, reaching ₹21.49 crore in Q4 FY25 before falling to ₹0.0 crore in Q1 FY26 and then rising to ₹5.69 crore in Q4 FY26 and ₹10.55 crore in Q1 FY27. Revenue declined to ₹4.0 crore in Q2 FY27. The company’s filings do not provide an explanation for this pattern.
Net profit was ₹0.21 crore in Q4 FY25, moved to a loss of ₹0.02 crore in Q3 FY26, and then recovered to ₹0.36 crore in Q1 FY27 before falling to ₹0.06 crore in Q2 FY27. The EBITDA margin reached 4.4% in Q1 FY27, compared with 1.8% in the latest quarter.
Which businesses drove the quarter?
The company reported revenue of ₹4.0 crore and EBIT of ₹0.11 crore from the Agro and Trading segment, with an EBIT margin of 2.8%. The Medical segment reported revenue of ₹0.01 crore and EBIT of ₹0.01 crore, with an EBIT margin of 100.0%.
The company stated that it had no reportable business segment and that segment-wise disclosure under Ind AS 108 was not required. Comparable year-ago revenue and EBIT figures were not provided for the reported segment categories.
| Segment | Revenue | Revenue YoY | EBIT | EBIT margin |
|---|---|---|---|---|
| Segment - Agro&Trading | 4 | 0.11 | 2.8% | |
| Segment- Securities | 0 | 0 | ||
| Segment- Medical | 0.01 | 0.01 | 100.0% | |
| Segment - Real estate | 0 | 0 | ||
| Segment - Textile | 0 | 0 | ||
| Unallocable | 0 | 0 |
Source: Company's results filing (XBRL segment data).
How did other Edible Oil companies do?
Among 13 Edible Oil companies compared for the quarter, the median revenue growth was 12.7% as of 6 November 2026. Eleven peers grew revenue faster than Integrated Proteins and two grew more slowly, based on the peer comparison for this quarter.
Profit rose for 9 of the 12 peers whose profit was compared. Integrated Proteins’ own revenue growth was lower than the peer median of 12.7% for the quarter.
| Integrated Proteins revenue growth (YoY) | −4.8% |
|---|---|
| Median of 13 other Edible Oil companies | +12.7% |
| Companies with slower revenue growth than Integrated Proteins | 2 of 13 |
| Companies with faster revenue growth than Integrated Proteins | 11 of 13 |
| Companies whose net profit rose | 9 of 12 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Integrated Proteins' revenue in Q2 FY27?
Revenue from operations was ₹4 crore, down 4.8% from ₹4.20 crore in Q2 FY26 (standalone).
Did Integrated Proteins make a profit in Q2 FY27?
Yes. Net profit was ₹0.06 crore, against a net profit of ₹0.05 crore in Q2 FY26.
What was Integrated Proteins' EPS in Q2 FY27?
Basic earnings per share were ₹0.03, against ₹0.16 in Q2 FY26.
When did Integrated Proteins announce its Q2 FY27 results?
On 5 November 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Board Meeting (BSE, 30 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Boardc Meeting Held On 5Th November, 2026 (BSE, 5 November 2026) · PDF
- Financial Result For The Quarter And Half Year Ending On 30/09/2026 (BSE, 5 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.